The phenotype of axial spondyloarthritis: is it dependent on HLA‐B27 status?

The phenotype of axial spondyloarthritis: is it dependent on HLA‐B27 status?

<p><strong>Objective:</strong> To describe the radiographic phenotype of axial spondyloarthritis (axSpA) according to the carriage of HLA‐B27.</p> <p><strong>Methods:</strong> An international collaboration compared the radiographic phenoty...

Full description

Bibliographic Details
Main Authors:	Coates, LC, Baraliakos, X, Blanco Garcia, F, Blanco-Morales, E, Braun, J, Chandran, V, Fernandez-Sueiro, JL, FitzGerald, O, Gallagher, P, Gladman, DD, Gubar, E, Korotaeva, T, Loginova, E, Lubrano, E, Mulero, J, Pinto, J, Queiro, R, Sanz, J, Szentpetery, A, Helliwell, PS
Format:	Journal article
Language:	English
Published:	Wiley 2020

Similar Items

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
by: Smolen, JS, et al.
Published: (2017)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
by: Braun, J, et al.
Published: (2023)

The genetic basis of spondyloarthritis: SPARTAN/IGAS 2009.
by: Evans, D, et al.
Published: (2010)

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
by: Poddubnyy, D, et al.
Published: (2021)

The Genetic Basis of Spondyloarthritis: SPARTAN/IGAS 2009 (vol 37, pg 2626, 2010)
by: Evans, D, et al.
Published: (2011)

The genetic basis of spondyloarthritis: SPARTAN/IGAS 2009 (Journal of Rheumatology (2010) 37 (2626-2631))
by: Evans, D, et al.
Published: (2011)

Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
by: Ahmed, S, et al.
Published: (2024)

Sustained very low disease activity and remission in psoriatic arthritis patients
by: Lubrano, E, et al.
Published: (2019)

Preface: Future trends in the field of spondyloarthritis
by: Sherlock, J, et al.
Published: (2018)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Features of spondyloarthritis around the world.
by: Lau, C, et al.
Published: (1998)

Pathogenic immune responses in Spondyloarthritis
by: Al-Mossawi, M
Published: (2016)

T cell phenotype and function in Spondyloarthritis
by: Ridley, AL
Published: (2013)

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort
by: Baraliakos, X, et al.
Published: (2023)

Quantitative MRI measurements of the Achilles tendon in spondyloarthritis using ultrashort echo times.
by: Hodgson, R, et al.
Published: (2012)

What should be the primary target of ‘treat to target’ in PsA?
by: Coates, L, et al.
Published: (2018)

What should be the primary target of "treat to target" in psoriatic arthritis?
by: Coates, LC, et al.
Published: (2018)

The role of HLA-B27 in spondyloarthritis.
by: Allen, R, et al.
Published: (1999)

T cell-mediated immune regulation in spondyloarthritis
by: Simone, D
Published: (2020)

Novel therapeutic targets in axial spondyloarthritis
by: Worth, C, et al.
Published: (2018)

Imaging of the Achilles tendon in spondyloarthritis: a comparison of ultrasound and conventional, short and ultrashort echo time MRI with and without intravenous contrast
by: Hodgson, R, et al.
Published: (2010)

Imaging of the Achilles tendon in spondyloarthritis: a comparison of ultrasound and conventional, short and ultrashort echo time MRI with and without intravenous contrast.
by: Hodgson, R, et al.
Published: (2011)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis
by: Kragstrup, T, et al.
Published: (2018)

The role of HLA-B27 in the pathogenesis of spondyloarthritis
by: McHugh, K
Published: (2011)

Performance and predictors of minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab
by: Coates, LC, et al.
Published: (2020)

Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative
by: De Marco, G, et al.
Published: (2020)

HLA-B27 HEAVY CHAIN DIMER EXPRESSION IN SPONDYLOARTHRITIS
by: Rysnik, O, et al.
Published: (2012)

Improving the management of psoriatic arthritis and axial spondyloarthritis: Roundtable discussions with healthcare professionals and patients
by: Garrido-Cumbrera, M, et al.
Published: (2017)

Qualitative interview study exploring the patient experience of living with axial spondyloarthritis and fatigue: difficult, demanding and draining
by: Pearson, N, et al.
Published: (2022)

Assessing fatigue in adults with axial spondyloarthritis: a systematic review of the quality and acceptability of patient-reported outcome measures
by: Pearson, N, et al.
Published: (2018)

Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
by: Catherine, S, et al.
Published: (2005)

PHENOTYPIC CHARACTERIZATION OF NATURAL KILLER CELLS AND RECEPTORS IN SPONDYLOARTHRITIS
by: Chan, A, et al.
Published: (2004)

BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO
by: Hammitzsch, A, et al.
Published: (2014)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Development of the Warwick axial spondyloarthritis fatigue and energy questionnaire (WASTEd)—a new patient-reported outcome measure
by: Pearson, NA, et al.
Published: (2022)

Axial spondyloarthritis: A new disease entity, not necessarily early ankylosing spondylitis
by: Robinson, P, et al.
Published: (2013)

Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis.
by: Robinson, P, et al.
Published: (2013)

Axial spondyloarthritis: A new disease entity, not necessarily early ankylosing spondylitis
by: Robinson, P, et al.
Published: (2012)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
by: Mease, PJ, et al.
Published: (2019)